论文部分内容阅读
医药研发外包作为知识流程外包的一种,在带来成本降低、效率提高、获得新技术、资源和财务配置更灵活等收益的同时也带来了一些潜在风险。近几年人们对于研发外包的风险也有了一定的关注和研究。中外文献中对于研发外包所涉及的风险有不同角度的分类和研究,但描述的具体风险具有共性,可以归纳为以下几类:政治/经济/宗教/文化风险、运营风险、创新能力/市场竞争力风险、信息安全/知识产权风险、合同风险以及合规风险。
As a kind of knowledge process outsourcing, pharmaceutical R & D outsourcing brings some potential risks while bringing the benefits of lower costs, higher efficiency, access to new technologies, more flexible resource and financial allocation. In recent years, there has been some concern and research on the risks of R & D outsourcing. Chinese and foreign literatures have classified and researched the risks involved in R & D outsourcing. However, the specific risks described are common and can be summarized into the following categories: political / economic / religious / cultural risks, operational risks, innovation / market competition Force Risk, Information Security / Intellectual Property Risk, Contract Risk and Compliance Risk.